The COVID-19 pandemic has raised considerable concerns that patients with inflammatory
bowel disease (IBD), particularly those treated with immunosuppressive therapies, may …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has prompted significant
changes in patient care in rheumatology and gastroenterology, with clinical guidance issued …

Background Intravenous [IV] infliximab is a well-established therapy for inflammatory bowel
diseases [IBD] patients. A subcutaneous [SC] formulation of infliximab [CT-P13] has recently …

Background There is a paucity of evidence to support safe and effective management of
patients with acute severe ulcerative colitis during the COVID-19 pandemic. We sought to …

Background and aims Healthcare quality improvement (QI) is the systematic process to
continuously improve the quality of care and outcomes for patients. The landmark …

Background Given the increasing health concerns for patients with inflammatory bowel
disease (IBD), amidst the COVID-19 pandemic, we investigated the impact of the pandemic …

Background: Recent trials support the clinical efficacy and safety of subcutaneous infliximab
(IFX) or vedolizumab (VDZ) for Inflammatory Bowel Disease (IBD). We evaluated the uptake …

Abstract Background and Aims There are concerns regarding the potential impact of the
COVID-19 outbreak on patients with inflammatory bowel disease [IBD]. We report on the …

Introduction The COVID-19 pandemic has disrupted training. Gastroenterology higher
specialty training is soon to be reduced from 5 years to 4. The British Society of …

In late 2019, reports arose of a new respiratory disease in China, identified as a novel
coronavirus, severe acute respiratory syndrome coronavirus 2. The World Health …